Boehringer wins accelerated approval for first-line use of lung cancer drug

Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated

AI Summary: Regulators accelerated approval of Boehringer Ingelheim’s lung cancer therapy for first‑line use, leveraging a priority review mechanism that sped the timeline. The label expansion places the drug into earlier treatment settings, reflecting promising data and the efficiency (and occasional controversy) of voucher‑assisted regulatory pathways.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month

FDA partially halts cancer trial following patient death and safety events / 3 months

FDA launches individualized therapy framework for ultra-rare diseases / 3 months

FDA makes one pivotal trial the default for drug approvals / 3 months

FDA refuses to review Moderna mRNA flu vaccine application / 3 months

FDA rejects Atara cell therapy for Epstein–Barr virus complications / 4 months

FDA commissioner Marty Makary resigns amid mounting scrutiny / 19 days